Ashish Tripathi
Directeur/Membre du Conseil chez Epigeneres Biotech Pvt Ltd.
Postes actifs de Ashish Tripathi
Sociétés | Poste | Début | Fin |
---|---|---|---|
Epigeneres Biotech Pvt Ltd.
Epigeneres Biotech Pvt Ltd. Pharmaceuticals: MajorHealth Technology Epigeneres Biotech Pvt Ltd. is an Indian company that focuses on detecting and treating cancer early. The company is based in Mumbai, India and was founded in 2012 by Anish Tripathi. In addition to their cancer detection technology, they also have a nutraceuticals business that specializes in molecular diagnostics and nutraceutical management for overall health and well-being. The company has developed a breakthrough technology based on the assumption that very small embryonic-like stem cells (VSELs) undergo epigenetic changes and get transformed into cancer stem cells (CSCs). The company's HRC test has the potential to detect cancer at stage zero, which significantly improves the cost, time, and chances of survival. | Directeur/Membre du Conseil | 29/02/2016 | - |
Historique de carrière de Ashish Tripathi
Statistiques
Internationale
Inde | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Epigeneres Biotech Pvt Ltd.
Epigeneres Biotech Pvt Ltd. Pharmaceuticals: MajorHealth Technology Epigeneres Biotech Pvt Ltd. is an Indian company that focuses on detecting and treating cancer early. The company is based in Mumbai, India and was founded in 2012 by Anish Tripathi. In addition to their cancer detection technology, they also have a nutraceuticals business that specializes in molecular diagnostics and nutraceutical management for overall health and well-being. The company has developed a breakthrough technology based on the assumption that very small embryonic-like stem cells (VSELs) undergo epigenetic changes and get transformed into cancer stem cells (CSCs). The company's HRC test has the potential to detect cancer at stage zero, which significantly improves the cost, time, and chances of survival. | Health Technology |
- Bourse
- Insiders
- Ashish Tripathi
- Expérience